Showing results (391-400 of 418) with videos related to
Sort By:
Pageof 42
Tumori|September 15, 2025
The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectivesAlberto Zambelli, Riccardo Gerosa, Michela Cinquini, et al.Journal of Cancer Policy|January 14, 2026
Defining the Role and Competencies of the Medical Oncologist in Diagnostic and Therapeutic Care Pathways: Consensus Recommendations from the Italian Association of Medical Oncology (AIOM)Rossana Berardi, Francesca Rossi, Valentina Tarantino, et al.Immunotherapy|February 25, 2020
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa studyMelissa Bersanelli, Sebastiano Buti, Giuseppe Luigi Banna, et al.Journal for Immunotherapy of Cancer|February 17, 2022
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinationsAlessio Cortellini, Biagio Ricciuti, Victor R Vaz, et al.La Radiologia Medica|July 7, 2026
Request and reporting models for computed tomography in the multidisciplinary management of cancer patients: consensus between the Italian Society of Medical and Interventional Radiology (SIRM) and the Italian Society of Medical Oncology (AIOM)Vincenza Granata, Alessandro Serafini, Roberta Fusco, et al.Scientific Reports|June 17, 2026
Prognostic value of systemic inflammatory markers in avelumab maintenance for advanced urothelial carcinoma: the multicentric SAILOR analysisBrigida Anna Maiorano, Giandomenico Roviello, Alessandro Rizzo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2026
International Consensus-Driven Recommendations for Patient-Reported Outcome Research Objectives in Early Phase Dose-Finding Oncology Trials: OPTIMISE-ROREmily Alger, Olalekan Lee Aiyegbusi, Amylou C Dueck, et al.Ebiomedicine|September 20, 2024
Post-surgery sequelae unrelated to disease progression and chemotherapy revealed in follow-up of patients with stage III colon cancerAlexia Mirandola, Andrei Kudriavtsev, Catalina Isabel Cofre Muñoz, et al.Plos One|September 20, 2019
Characteristics of prescription in 29 Level 3 Neonatal Wards over a 2-year period (2017-2018). An inventory for future researchBéatrice Gouyon, Séverine Martin-Mons, Silvia Iacobelli, et al.European Journal of Cancer (Oxford, England : 1990)|July 23, 2019
A validated prognostic classifier for <sup>V600E</sup>BRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' studyFotios Loupakis, Rossana Intini, Chiara Cremolini, et al.Pageof 42